# The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuxi

Source: https://onco.cc/trials/nct07204574/  
OnCo record `nct07204574` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of bevacizumab (glioblastoma use), cetuximab and fOLFOX (5-FU, leucovorin, oxaliplatin) in colorectal cancer, run by Chang Gung Memorial Hospital, now recruiting.

## Summary

The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer is a phase 1/2, interventional study registered as NCT07204574 by Chang Gung Memorial Hospital, with a registry enrolment figure of 40 participants, started 2025-05-14 and due to reach its primary completion in 2025-12-31. Interventions recorded: HCB101; Bevacizumab; Cetuximab (Erbitux); FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan); FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil). Conditions listed: CRC. Primary outcome: Number of subjects with MTD of HCB101 in combination with Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI; Overall Rate Response (ORR). Colorectal eligibility wording from the registry: "With histologically/cytologically confirmed diagnosis of unresectable locally advanced or metastatic colorectal cancer, with both RAS and BRAF wild-type, who have experienced treatment failure with prior chemotherapy for locally advanced or metastatic disease (intended for second-line treatment)". Sites: Taiwan. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07204574
- Phase: 1/2
- Setting: The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer
- Sponsor: Chang Gung Memorial Hospital
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT07204574: https://clinicaltrials.gov/study/NCT07204574

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/), [Cetuximab](https://onco.cc/drugs/cetuximab/), [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07204574.json